Trial Outcomes & Findings for A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension (NCT NCT01781962)

NCT ID: NCT01781962

Last Updated: 2014-07-31

Results Overview

The angle width formed between the eye's cornea and iris in both eyes was measured in microns (µm) using AS OCT, a laser-based, noninvasive, diagnostic system providing high-resolution images of the eye.

Recruitment status

TERMINATED

Target enrollment

206 participants

Primary outcome timeframe

Day 1

Results posted on

2014-07-31

Participant Flow

Participant milestones

Participant milestones
Measure
All Participants
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Overall Study
STARTED
206
Overall Study
COMPLETED
201
Overall Study
NOT COMPLETED
5

Reasons for withdrawal

Reasons for withdrawal
Measure
All Participants
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Overall Study
Other Miscellaneous Reasons
5

Baseline Characteristics

A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Participants
n=206 Participants
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Age, Customized
<45 years
111 Participants
n=5 Participants
Age, Customized
45 to 65 years
71 Participants
n=5 Participants
Age, Customized
>65 years
24 Participants
n=5 Participants
Sex: Female, Male
Female
91 Participants
n=5 Participants
Sex: Female, Male
Male
115 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 1

Population: Participants from the Modified Intent-to-treat (mITT) population, all enrolled patients with both gonioscopy and AS OCT measurements, with evaluable data for this outcome measure.

The angle width formed between the eye's cornea and iris in both eyes was measured in microns (µm) using AS OCT, a laser-based, noninvasive, diagnostic system providing high-resolution images of the eye.

Outcome measures

Outcome measures
Measure
All Participants
n=330 Eyes
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Anterior Angle Width Using Anterior Segment Optical Coherence Tomography (AS OCT)
638.8 µm
Standard Deviation 272.67

SECONDARY outcome

Timeframe: Day 1

Population: Participants from the mITT population, all enrolled patients with both gonioscopy and AS OCT measurements, with data available for this outcome measure.

The angle width formed between the cornea and iris in both eyes was measured by gonioscopy using Shaffer grading where: grade 4=wide open, grade 3=moderately open, grade 2=moderately narrow, grade 1=very narrow or grade 0=closed. The number of eyes in each Shaffer Grade is reported.

Outcome measures

Outcome measures
Measure
All Participants
n=405 Eyes
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens
Grade 1
1 eye
NA
Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens
Grade 2
1 eye
NA
Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens
Grade 3
34 eye
334.86
Number of Study Eyes in Each Shaffer Grade Using Gonioscopic Lens
Grade 4
369 eye
262.33

SECONDARY outcome

Timeframe: Day 1

Population: Participants from the mITT population, all enrolled patients with both gonioscopy and AS OCT measurements, with data available for this outcome measure.

The angle width formed between the cornea and iris in both eyes was measured by gonioscopy using Large Step Grading ranging from 1.0 (smallest angle width) to 7.5 (largest angle width) with 0.5 unit intervals where each Large Step unit represented a fixed length of approximately 200 µm. The number of eyes in each Large Step Grade is reported.

Outcome measures

Outcome measures
Measure
All Participants
n=405 Eyes
Open-Angle Glaucoma (OAG) and/or Ocular Hypertension (OHT) patients.
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 1.0
0 eye
126.92
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 1.5
4 eye
203.66
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 2.0
36 eye
206.72
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 2.5
32 eye
212.36
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 3.0
78 eye
191.87
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 3.5
24 eye
234.94
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 4.0
69 eye
290.20
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 4.5
23 eye
208.44
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 5.0
34 eye
119.57
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 5.5
9 eye
221.46
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 6.0
33 eye
184.16
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 6.5
28 eye
294.97
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 7.0
28 eye
158.44
Number of Study Eyes in Each Step Grade Using Gonioscopic Lens
Step Grade 7.5
7 eye

Adverse Events

All Participants

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Therapeutic Area Head,

Allergan, Inc

Phone: 714-246-4500

Results disclosure agreements

  • Principal investigator is a sponsor employee A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is at least 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER